Review
The meaning of hypokalemia in heart failure

https://doi.org/10.1016/j.ijcard.2011.06.121Get rights and content

Abstract

Maintenance of normal potassium (K+) homeostasis has become an increasingly important limiting factor in the therapy of heart failure (HF). With the application of loop diuretics and digoxin, hypokalemia has become a frequent and feared side effect of treatment. Low serum K+ in HF may be also a marker of increased neurohormonal activity and disease progression.

To gain the maximum benefit from treatment, we need to individualize drug use and carefully monitor electrolytes. Symptomatic HF patients (New York Heart Association class III–IV) should be prescribed the lowest dose of diuretic necessary to maintain euvolemia. Mild hypokalemia may be corrected by the use of aldosterone receptor antagonists such as spironolactone or eplerenone. However, a more severe hypokalemia should preferably be corrected using K+ supplement. Serum K levels should be frequently checked and maintained between 4.0 and 5.5 mEq/l (mmol/l).

Section snippets

Epidemiology of hypokalemia in heart failure (HF)

Congestive heart failure carries a grim prognosis. The 5-year survival rate is well below 40% [1], with half of the deaths classified as sudden [2], [3]. These deaths were probably caused by ventricular arrhythmias or electromechanical dissociation [4], [5], [6]. Electrophysiological remodeling is associated with the progression of hypertrophy and heart failure (HF) [7].

Potassium (K+) is an important electrolyte essential for a healthy nervous system and a regular heart rhythm [7], [8]. K+

Etiology and pathophysiology of hypokalemia in HF

The sodium-rich diet of modern humans may produce sodium overload and K+ depletion [10]. Hypokalemia contributes to the pathogenesis of cardiovascular disease, and many cardiovascular disorders and drugs cause hypokalemia [11], [12].

Patients with HF may have difficulty with K+ transport into tissues. In patients with HF, an increase in oxidative stress may result in a defect in Na+/K+-ATPase activity and thus in transport of K+ into tissues. Consequently, tissue levels of K+ may be considerably

Effect of hypokalemia in HF

Hypokalemia causes cellular hyperpolarity, increases resting potential, hastens depolarization, and increases automaticity and excitability [31], [32]. Because cardiac repolarization relies on K+ influx, hypokalemia lengthens the action potential and increases QT dispersion reflecting electrical inhomogeneity. Most patients with HF have increased ventricular ectopy, and 50% exhibit nonsustained ventricular tachycardia [33]. A total of 50% of deaths from HF are sudden, presumably due to

Prevention and treatment of hypokalemia in HF

The combination drug therapy may simultaneously improve clinical outcomes while it enhances the risk of K+-related adverse events [47]. The K+-sparing diuretics are important in preventing hypokalemia in HF [47].

The K+-sparing diuretics include spironolactone and eplerenone. Unlike loop and thiazide diuretics, these drugs do not act directly on sodium transport. Some drugs in this class antagonize the actions of aldosterone (aldosterone receptor antagonists) at the distal segment of the distal

Potassium supplements in HF patients

K+ supplements are commonly used to treat hypokalemia and maintain normokalemia. However, their long-term effects on outcomes in chronic heart failure are unknown. Ekundayo et al. used a public-use copy of the Digitalis Investigation Group (DIG) trial dataset to determine the association of K+ supplement use with outcomes with a propensity-matched design. Although the use of K+ supplements in chronic heart failure was not associated with mortality (HR when K+ supplement use was compared with

Conclusions

Hypokalemia is common in HF patients, often due to a defect in Na+/K+-ATPase activity and intracellular shift of K caused by oxidative stress and neurohormonal activation. Serum K+ levels have important therapeutic and prognostic implication for HF patients. While diuretics, commonly used in HF may cause hypokalemia, neurohormonal blockade using ACE inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists may cause hyperkalemia. Hypokalemia is associated with

Declaration of interest

The authors have not received any payments in connection with the preparation of this review. No pharmaceutical company supported or was involved with the preparation of this article.

Acknowledgement

The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [62].

References (62)

  • A. Ahmed et al.

    Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial

    Int J Cardiol

    (2008)
  • C.V. Leier et al.

    Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia

    Am Heart J

    (1994)
  • M.A. Perazella

    Drug-induced hyperkalemia: old culprits and new offenders

    Am J Med

    (2000)
  • H. Schepkens et al.

    Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

    Am J Med

    (2001)
  • M. Svensson et al.

    How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

    J Card Fail

    (2004)
  • X. Gao et al.

    Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure

    J Card Fail

    (2007)
  • O.J. Ekundayo et al.

    Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study

    Int J Cardiol

    (2010)
  • L.G. Shewan et al.

    Ethics in the authorship and publishing of scientific articles

    Int J Cardiol

    (2010)
  • W.B. Kannel et al.

    Changing epidemiological features of cardiac failure

    Br Heart J

    (1994)
  • J.N. Cohn et al.

    Effects of vasodilator therapy on mortality in chronic congestive heart failure: a result of a veterans affairs comparative study (V-HEFT)

    New Engl J Med

    (1986)
  • J.N. Cohn et al.

    A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure

    New Engl J Med

    (1991)
  • F.C. Kempf et al.

    Cardiac arrest recorded on ambulatory electrocardiograms

    Am J Cardiol

    (1984)
  • M. Luu et al.

    Diverse mechanisms of unexpected cardiac arrest in advanced heart failure

    Circulation

    (1989)
  • W.G. Stevenson et al.

    Sudden death prevention in patients with advanced ventricular dysfunction

    Circulation

    (1993)
  • G.F. Tomaselli et al.

    Electrophysiological remodeling in hypertrophy and heart failure

    Cardiovasc Res

    (1999)
  • I. Dursun et al.

    Difficulties in maintaining potassium homeostasis in patients with heart failure

    Clin Cardiol

    (2006)
  • M. Schulman et al.

    Hypokalemia and cardiovascular disease

    Am J Cardiol

    (1990)
  • A.W. Hoes et al.

    Do non-potassium sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence

    Drugs

    (1994)
  • A. Delgado-Almeida et al.

    Changes in plasma ionized calcium and RBC K content in severe hyperkalemia: new electrocardiographic concept

    Circulation

    (2006)
  • J.N. Cohn et al.

    New guidelines for potassium replacement in clinical practice. A contemporary review by the National Council on Potassium in Clinical Practice

    Arch Intern Med

    (2000)
  • J.G. Cleland et al.

    Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension

    Br Heart J

    (1987)
  • Cited by (59)

    • Consequences of COVID-19 on the cardiovascular and renal systems

      2022, Sleep Medicine
      Citation Excerpt :

      One cohort study [99] of 175 patients of COVID-19 reported that 55% patients developed hypokalemia (18% with severe hypokalemia), whereas the proportion of hypokalemia among critically ill patients reached 85%. The authors also mentioned that hypokalemia might be associated with enhanced potassium excretion, which was secondary to activation of the RAAS, caused by the reduction in ACE2 activity [99,134]. However, other researchers believed that hypokalemia might also be secondary to diarrhea induced by SARS-CoV-2, the use of diuretics or other drugs, and cannot be simply explained by activation of the RAAS, at least more evidence should be presented [135].

    • Essential metals in health and disease

      2022, Chemico-Biological Interactions
      Citation Excerpt :

      Renal loss of potassium is a rather complex problem and may occur from the adverse effect of anticancer therapy (cis-platin) or use of antibiotics (gentamicin, penicillin) or diuretics. Hypokalemia occurs among patients with congestive heart failure as a result of altered of Na,K-pump activity, with an oxidative stress-modified distribution of potassium and neurohormonal activation [40]. Heart failure is known to stimulate metabolic changes such as insulin resistance, which may exacerbate the initial condition [41].

    • Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients

      2020, International Journal of Infectious Diseases
      Citation Excerpt :

      The role of gastrointestinal symptoms in the development of hypokalemia is not supported by the present study results, in accordance with cohort data from China (Chen et al., 2020a). Aside from being a marker of severity, the clinical relevance of hypokalemia in this clinical setting lies in the fact that it would potentially contribute to myocardial dysfunction, ventricular arrhythmia (Bielecka-Dabrowa et al., 2012), and respiratory muscle dysfunction. Nonetheless, the impact of hypokalemia on myocardial and respiratory function in COVID-19 patients is not clear, and direct evidence demonstrating that SARS-CoV-2 infects the human heart and decreases ACE2 expression is currently lacking.

    • Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review

      2020, Journal of the American College of Cardiology
    • Evaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure

      2020, Nutrition, Metabolism and Cardiovascular Diseases
      Citation Excerpt :

      Some aspects of our study warrant discussion. Patients were stratified based on LD usage and spironolactone usage primarily because these medications are known to directly increase the risk of hypo and hyper-kalemia within this population [24,25]. Nevertheless, other medical therapies such as angiotensin receptor blockers, angiotensin-converting enzyme inhibitors and B-blockers are also known to cause disturbances in potassium balance [45].

    View all citing articles on Scopus
    View full text